Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis: 1-year results from mobile

被引：0

作者：

Reginster, JY

Zikan, V

Lorenc, R

Hughes, C

Mairon, N

Bonvoisin, B

Stakkestad, JA

机构：

[1] Univ Liege, B-4000 Liege, Belgium

[2] Charles Univ, CR-11636 Prague, Czech Republic

[3] Childrens Mem Inst, Warsaw, Poland

[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[5] CECOR AS, Haugesund, Norway

来源：

BONE | 2005年 / 36卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S416 / S416

页数：1

共 50 条

[31] Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis
Akesson, K
Beusterien, K
Hebborn, A
Leidy, NK
[J]. BONE, 2005, 36 : S417 - S418
[32] Daily and once-monthly oral ibandronate have similar safety profiles in elderly and younger women: 1-year results from the mobile study.
Miller, P
Lewiecki, M
Sol, E
[J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S194 - S194
[33] Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE.
Recker, RR
Kendler, DL
Adami, S
Hughes, C
Dumont, E
Schimmer, RC
Cooper, C
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
[34] Weekly dosing of oral ibandronate is effective in the prevention of postmenopausal osteoporosis
Felsenberg, D
Christiansen, C
Cerwinski, E
Burdeska, A
Jonkanski, I
Meinert, R
[J]. OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S16 - S17
[35] EFFICACY OF ONCE-MONTHLY ORAL BISPHOSPHONATES (IBANDRONATE AND RISEDRONATE) IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
Epstein, S.
McCloskey, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 146 - 146
[36] Once-monthly oral ibandronate (boniva) has favorable safety and tolerability in postmenopausal women with osteoporosis: 2-year results from MOBILE.
Greenwald, M
Hawker, G
Cooper, C
Hughes, C
Mairon, N
Bonvoisin, B
Silverman, S
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S297 - S297
[37] Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (vol 65, pg 654, 2006)
Reginster, J-Y
Adami, S.
Lakatos, P.
Greenwald, M.
Stepan, J. J.
Silverman, S. L.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 280 - 280
[38] Safety profile of once-monthly oral ibandronate: MOBILE 2-year results
Bolognese, M
Luckey, M
Miller, P
Civitelli, R
[J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2005, 12 (06): : 793 - 793
[39] Response to once-monthly and daily oral ibandronate in the mobile study: 2-year analysis
不详
[J]. CALCIFIED TISSUE INTERNATIONAL, 2006, 78 : S145 - S145
[40] Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: Results of BALTO II
Hadji, P.
Benhamou, C. -L.
Devas, V.
Masanauskaite, D.
Barrett-Connor, E.
[J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S69 - S69

← 1 2 3 4 5 →